Dogwood Therapeutics, Inc.
General ticker "DWTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $67.8M (TTM average)
Dogwood Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -28.7%.
Estimated limits based on current volatility of 5.8%: low 1.05$, high 1.18$
Factors to consider:
- Total employees count: 8 (-33.3%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient capital, Clinical trial failure, Regulatory and compliance, Commercialization challenges, Intellectual property risks
- Current price 62.2% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.86$, 8.07$]
- 2026-12-31 to 2027-12-31 estimated range: [2.14$, 6.35$]
Financial Metrics affecting the DWTX estimates:
- Negative: with PPE of -0.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of 83.06 > 81.82
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: Investing cash flow per share per price, % of 0 <= 2.40
- Negative: -0.26 < Industry inventory ratio change (median), % of 0
- Negative: negative Net income
Short-term DWTX quotes
Long-term DWTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $5.45MM | $12.23MM | $27.97MM |
| Operating Income | $-5.45MM | $-12.23MM | $-27.97MM |
| Non-Operating Income | $0.15MM | $-0.12MM | $-6.07MM |
| R&D Expense | $1.73MM | $3.53MM | $21.87MM |
| Income(Loss) | $-5.30MM | $-12.35MM | $-34.04MM |
| Taxes | $0.00MM | $-0.00MM | $0.22MM |
| Net Income(Loss)* | $-5.30MM | $-12.35MM | $-34.26MM |
| Stockholders Equity | $3.81MM | $-10.12MM | $74.90MM |
| Assets | $4.17MM | $94.31MM | $90.17MM |
| Operating Cash Flow | $-4.87MM | $-8.79MM | $-15.62MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $0.00MM | $3.76MM | $0.00MM |
| Financing Cash Flow | $1.16MM | $16.70MM | $7.28MM |
| Earnings Per Share** | $-7.05 | $-12.02 | $-4.17 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.